- Home
- KRO vs PRTA Comparison
KRO vs PRTA Comparison
Compare KRO & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KRO | PRTA |
|---|---|---|
| Founded | 1916 | 2012 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 503.9M | 595.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | KRO | PRTA |
|---|---|---|
| Price | $4.49 | $10.73 |
| Analyst Decision | Strong Sell | Buy |
| Analyst Count | 2 | 9 |
| Target Price | $6.50 | ★ $18.86 |
| AVG Volume (30 Days) | 299.8K | ★ 602.7K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | ★ 4.44% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,864,200,000.00 | $11,786,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.29 | $819.08 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 0.01 | N/A |
| 52 Week Low | $4.08 | $4.32 |
| 52 Week High | $10.71 | $17.66 |
Technical Indicators
Market Signals| Indicator | KRO | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 42.54 | 55.81 |
| Support Level | $4.65 | $10.14 |
| Resistance Level | $4.96 | $11.57 |
| Average True Range (ATR) | 0.26 | 0.57 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 22.03 | 56.59 |
Price Performance
Historical ComparisonAbout KRO Kronos Worldwide Inc
Kronos Worldwide Inc manufactures and sells titanium dioxide pigments. Titanium dioxide is a white inorganic pigment used in various products. The majority of Kronos' sales come from titanium dioxide used for coatings on automobiles, aircraft, machines, appliances, traffic paint, and in both commercial and residential interiors and exteriors. The second product category is titanium dioxide used for plastics such as packaging materials and food packaging, houseware, appliances, toys, and computer cases. The majority of revenue comes from the United States.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.